Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors (ACEi) and Angiotensin-Receptor Blockade (ARB) Users in the COPDGene® Cohort

Tejwani, Vickram; Fawzy, Ashraf; Putcha, Nirupama; Castaldi, Peter J.; Cho, M.H.; Pratte, Katherine; Bhatt, Surya P.; Lynch, David A.; Humphries, S.M.; Kinney, Gregory L.; D’Alessio, Franco R.; Hansel, Nadia N.

doi:10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2292

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…106 On the contrary, emphysema development is slowed by both ACE inhibitors and AT1 receptor antagonists, regardless of current or former smoking status. 106 Furthermore, ACE inhibitors and AT1 receptor antagonists are associated with a reduced risk of pneumonia in patients with COPD. 107 Even more important is the documentation that the use of ACE inhibitor/ AT1 receptor antagonists before hospitalization was associated with a reduction in mortality in patients with COPD exacerbation and acute respiratory failure.…”

Section: Potential Pulmonary Risks For Patients With Cad When Using D...mentioning

confidence: 99%

“…105 However, there is also evidence that the use of AT1 receptor blocker is associated with an attenuated decrease in lung function, particularly in former smokers. 106 On the contrary, emphysema development is slowed by both ACE inhibitors and AT1 receptor antagonists, regardless of current or former smoking status. 106 Furthermore, ACE inhibitors and AT1 receptor antagonists are associated with a reduced risk of pneumonia in patients with COPD.…”

Section: Cardiovascular Diseasementioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Cazzola

Rogliani

Ora

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Chronic airway diseases (CAD), mainly asthma and chronic obstructive pulmonary disease (COPD), are frequently associated with different comorbidities. Among them, cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) pose problems for the simultaneous treatment of CAD and comorbidity. Indeed, there is evidence that some drugs used to treat CAD negatively affect comorbidity, and, conversely, some drugs used to treat comorbidity may aggravate CAD. However, there is also growing evidence of some beneficial effects of CAD drugs on comorbidities and, conversely, of the ability of some of those used to treat comorbidity to reduce the severity of lung disease. In this narrative review, we first describe the potential cardiovascular risks and benefits for patients using drugs to treat CAD and the potential lung risks and benefits for patients using drugs to treat CVD. Then, we illustrate the possible negative and positive effects on T2DM of drugs used to treat CAD and the potential negative and positive impact on CAD of drugs used to treat T2DM. The frequency with which CAD and CVD or T2DM are associated requires not only considering the effect that drugs used for one disease condition may have on the other but also providing an opportunity to develop therapies that simultaneously favorably impact both diseases.

show abstract

Section: Potential Pulmonary Risks For Patients With Cad When Using D...mentioning

confidence: 99%

Section: Cardiovascular Diseasementioning

confidence: 99%

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Cazzola

Rogliani

Ora

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors (ACEi) and Angiotensin-Receptor Blockade (ARB) Users in the COPDGene® Cohort

Cited by 1 publication

References 0 publications

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Contact Info

Product

Resources

About